Fig. 3

CD11c expression is correlated with activation of tumor-infiltrating CD8⁺ T cells. a EG7 tumor bearing mice were treated with OVA or OVA + Poly(I:C) at day 9. Six days later, tumors were harvested and the proportions of OVA-specific CD8⁺ T cells and CD11c⁺ CD8⁺ T cells were evaluated on flow cytometer. b CD11c expression level on intratumor CD8⁺ T cells was evaluated on flow cytometer. Gating strategy is shown in the left panels, and the CD11c expression levels on CD11c⁺ CD8⁺ T cells are shown in the right panel. c The proportions of OVA-specific populations on intratumor CD11c⁻ , CD11c^lo-mid and CD11c^hi CD8⁺ T cells were evaluated on flow cytometer. Gating strategy is shown in the left panel. Error bars show ± SEM; n = 5 per group. Student’s t-test was performed to analyze statistical significance. * p < 0.05(a-c). d-e CD11c⁻ , CD11c^lo-mid and CD11c^hi CD8⁺ T cells (d) or OVA + Poly(I:C)-stimulated OVA-tetramer⁺ CD11c⁻ and CD11c⁺ CD8⁺ T cells (e) were isolated from tumor tissues by FACS sorting at day 15. The gene expression levels were measured by quantitative PCR. Error bars show ± SD (d, e). The results are one of the two independent experiments